Moderna and Merck’s intismeran autogene, a personalized mRNA cancer vaccine encoding up to 34 patient-specific neoantigens, drove recent sentiment after its Phase 3 INTerpath-001 trial in resected high-risk melanoma met endpoints. Combined with Keytruda, it cut recurrence or death risk by 42% and distant metastasis risk by 38% versus Keytruda alone at roughly two years’ follow-up, with data presented at ESMO in October 2026. The companies are now engaging regulators toward a U.S. BLA filing, with Moderna projecting a potential 2027 launch if approved. No submission has occurred yet, and traders are watching for an official filing announcement, FDA acceptance, or competing DNA/plasmid vaccine progress such as Scancell’s iSCIB1+ fast-track program. Positive survival or subgroup data could further accelerate timelines, while any delays in manufacturing personalized doses or regulatory requests for longer follow-up would slow momentum.
基于Polymarket数据的AI实验性摘要。这不是交易建议,也不影响该市场的结算方式。 · 更新于1H6H1D7D30DALL
View resolved

警惕外部链接哦。
警惕外部链接哦。
常见问题